#ivonescimab

[zman1175]

This Stock Is Up Over 6x More Than Nvidia in 2024 !

[drcare4u]

Frontline Ivonescimab May Further Reduce Progression or Death Risk Versus Keytruda in NSCLC Subset

Frontline Ivonescimab May Further Reduce Progression or Death Risk Versus Keytruda in NSCLC Subset For patients with PD-L1-positive advanced non-small cell lung cancer (NSCLC), frontline treatment via ivonescimab resulted in a 49% reduction in the risk of disease progression or death when compared to treatment with Keytruda (pembrolizumab), study findings have shown. Findings from the primary…

[fmarkets]

2. Summit Therapeutics Inc. Shows Promise with Innovative Ivonescimab Drug in Financial Fourth Quarter of 2023 https://csimarket.com/stocks/news.php?code=SMMT&date=2024-02-20155348&utm_source=dlvr.it&utm_medium=tumblr

[newzzwired]

Week In Review: Akeso Out-Licenses PD-1/VEGF To Summit In $5 Billion Pact

Week In Review: Akeso Out-Licenses PD-1/VEGF To Summit In $5 Billion Pact

wacomka Deals and Financings In a blockbuster agreement, Guangzhou’s Akeso (OTCPK:AKESF) out-licensed ex-China rights to its bispecific PD-1/VEGF candidate in a deal worth up to $5 billion (see story). Summit Therapeutics (SMMT) of Menlo Park, CA will pay $500 million upfront and up to $4.5 billion in milestones, plus single digit royalties for rights to develop ivonescimab in the US, Canada,…